[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"patients-who-undergo-pancreaticoduodenectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:patients-who-undergo-pancreaticoduodenectomy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100632511","phase-2-safety-and-efficacy-of-anricfen-for-postoperative-analgesia-and-rehabilitation-promotion-after-pancreaticoduodenectomyintervention-measures-for-normal-adults-administer-ariceptin-injection-intravenously-post-operation-at-a-dose-of-1-gkgevery-8-hours-for-three-consecutive-days-after-surgery-100632511",false,"NCT07514637","Safety and Efficacy of Anricfen for Postoperative Analgesia and Rehabilitation Promotion After Pancreaticoduodenectomy.Intervention Measures: For Normal Adults, Administer Ariceptin Injection Intravenously Post-operation at a Dose of 1 μg\u002FKgevery 8 Hours for Three Consecutive Days After Surgery.","The Safety and Efficacy of Aniracetamfen for Postoperative Analgesia and Rehabilitation After Pancreaticoduodenectomy: A Single-center, Single-arm Clinical Study","Inclusion Criteria:\n\n* Patients who underwent pancreatic surgery, including pancreaticoduodenectomy (PD), pancreatic-preserving pancreaticoduodenectomy (PPPD), and laparoscopic pancreaticoduodenectomy (LPD)\n* Age ≥ 18 years old and \\\u003C 80 years old\n* ASA Ⅰ-Ⅲ\n* Be able to clearly understand and voluntarily participate in the research\n\nExclusion Criteria:\n\n* Merging severe primary diseases involving the heart, brain, liver, kidneys and hematopoietic system\n* History of long-term use of psychotropic drugs and cognitive dysfunction\n* Having a history of acute poisoning from alcohol, sleeping pills, painkillers or other drugs that affect the central nervous system\n* Pregnancy or lactation period\n* History of allergy to NSAIDs, opioids, or to the test medication\n* Drug users, alcoholics, and opiate abusers\n* Those who had a history of chronic pain before the operation and a history of long-term use of analgesics and\u002For sedatives\n* Those who had thyroid dysfunction before the operation","ALL","18 Years","80 Years",{"count":20,"type":21},35,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Exploring the effectiveness and safety of early use of Ariceptinfen after pancreaticoduodenectomy in alleviating postoperative pain and promoting recovery of patients.\n\nMain objective: To explore the analgesic effect of Anricfen after pancreaticoduodenectomy.\n\nSecondary objective: To explore the impact of Anricfen on the accelerated recovery after pancreaticoduodenectomy.\n\nExploratory objective: To investigate the biomarkers of Anricfen's analgesic effect after pancreaticoduodenectomy, as well as its correlation factors with tumor pathology.",[27],"Patients Who Undergo Pancreaticoduodenectomy",[29,30,31,32],"pancreaticoduodenectomy","Peripheral κ receptor agonist","analgesia","Promote recovery","RECRUITING","2026-04-01",{"date":36,"type":37},"2026-04-07","ACTUAL",{"date":39,"type":37},"2025-11-25",{"date":41,"type":21},"2026-03-31",{"name":43,"class":44},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER"]